Emerging drugs to treat juvenile idiopathic arthritis

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Expert Opinion on Emerging Drugs

• Publication date

  2011-08-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14728214.2011.581662PMID 21529300
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features

  2011cited by this paper
• Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO)

  2011cited by this paper
• Malignancies in Juvenile Idiopathic Arthritis: A Preliminary Report

  2011cited by this paper
• Pediatric rheumatology: JIA, treatment and possible risk of malignancies

  2011cited by this paper
• An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.

  2011cited by this paper
• Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis.

  2011cited by this paper
• A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial): Commentary

  2011cited by this paper
• Analysis of disease activity, functional disability and articular damage in patients with juvenile idiopathic arthritis: a prospective outcome study.

  2011cited by this paper
• Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.

  2011cited by this paper
• Juvenile Idiopathic Arthritis

  2011influential reference
• Report on malignancies in the German juvenile idiopathic arthritis registry.

  2011cited by this paper
• Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I

  2011cited by this paper
• LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study.

  2010cited by this paper
• Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs.

  2010cited by this paper
• Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I

  2010cited by this paper
• Abatacept improves health‐related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis

  2010cited by this paper
• Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis.

  2010cited by this paper
• EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

  2010cited by this paper
• Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.

  2010cited by this paper
• Mixed results with modulation of TH-17 cells in human autoimmune diseases

  2010cited by this paper
• Synovial and inflammatory diseases in childhood: role of new imaging modalities in the assessment of patients with juvenile idiopathic arthritis

  2010cited by this paper
• Current therapeutic approaches to autoimmune chronic uveitis in children.

  2010cited by this paper
• Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.

  2010cited by this paper
• Biologic similarities based on age at onset in oligoarticular and polyarticular subtypes of juvenile idiopathic arthritis.

  2010cited by this paper
• An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.

  2010cited by this paper
• Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis.

  2010cited by this paper
• Denosumab‐mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients

  2010cited by this paper
• Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes.

  2010cited by this paper
• The transient nature of the Th17 phenotype

  2010cited by this paper
• Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration.

  2010cited by this paper
• Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

  2010cited by this paper
• The safety profile of biologic therapies for juvenile idiopathic arthritis

  2010cited by this paper
• Randomized, double‐blind, placebo‐controlled trial of the oral interleukin‐12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease

  2010cited by this paper
• Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis

  2010cited by this paper
• Targeting IL-17 and Th17 cells in rheumatoid arthritis.

  2010influential reference
• Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment

  2010cited by this paper
• Development and preliminary validation of a paediatric-targeted MRI scoring system for the assessment of disease activity and damage in juvenile idiopathic arthritis

  2010cited by this paper
• Targeting the B cell in rheumatoid arthritis.

  2010influential reference
• Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study.

  2010cited by this paper
• Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial.

  2010cited by this paper
• The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.

  2009cited by this paper
• Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension

  2009cited by this paper
• Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations.

  2009cited by this paper
• Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis

  2009cited by this paper
• Th17 Transcription Factor RORC2 Is Inversely Correlated with FOXP3 Expression in the Joints of Children with Juvenile Idiopathic Arthritis

  2009cited by this paper
• IL-17 as a future therapeutic target for rheumatoid arthritis

  2009influential reference
• Phenotypic and functional characterization of switch memory B cells from patients with oligoarticular juvenile idiopathic arthritis

  2009cited by this paper
• Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis

  2009cited by this paper
• Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets.

  2009cited by this paper
• Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis

  2009cited by this paper
• Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: a case report.

  2009cited by this paper
• Accuracy of Wallace Criteria for Clinical Remission in Juvenile Idiopathic Arthritis: a Cohort Study of 761 Consecutive Cases

  2009cited by this paper
• Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates

  2009cited by this paper
• Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists.

  2009cited by this paper
• Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

  2009cited by this paper
• Impaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome

  2008cited by this paper
• Rituximab treatment in children: comment on the review by Looney et al.

  2008cited by this paper
• Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.

  2008cited by this paper
• Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register

  2008cited by this paper
• Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

  2008cited by this paper
• Therapeutic targeting of Janus kinases

  2008cited by this paper
• Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

  2008cited by this paper
• 2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension

  2008cited by this paper
• Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases.

  2008cited by this paper
• Comparison of Vancouver and International League of Associations for rheumatology classification criteria for juvenile psoriatic arthritis.

  2008cited by this paper
• The effects of rituximab on immunocompetency in patients with autoimmune disease.

  2008cited by this paper
• Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry

  2008cited by this paper
• Elevated serum receptor activator of NFκB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis

  2008cited by this paper
• A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children.

  2008cited by this paper
• Interleukin-17–producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers

  2008cited by this paper
• Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis.

  2008cited by this paper
• Osteoprotegerin/RANKL system imbalance in active polyarticular‐onset juvenile idiopathic arthritis: a bone damage biomarker?

  2008cited by this paper
• Assessing current outcomes of juvenile idiopathic arthritis: a cross-sectional study in a tertiary center sample.

  2008cited by this paper
• Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis.

  2008cited by this paper
• Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.

  2008cited by this paper
• Magnetic resonance imaging, ultrasonography, and conventional radiography in the assessment of bone erosions in juvenile idiopathic arthritis.

  2008cited by this paper
• Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

  2008cited by this paper
• Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL

  2007cited by this paper
• Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations.

  2007cited by this paper
• The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis

  2007cited by this paper
• Juvenile idiopathic arthritis.

  2007cited by this paper
• A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.

  2007cited by this paper
• Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis.

  2007cited by this paper
• Erosive arthritis

  2007cited by this paper
• A longitudinal analysis of physical functional disability over the course of juvenile idiopathic arthritis

  2007cited by this paper
• Specific gene expression profiles in systemic juvenile idiopathic arthritis.

  2007influential reference
• Remission in juvenile idiopathic arthritis.

  2006cited by this paper
• Lymphoid neogenesis in juvenile idiopathic arthritis correlates with ANA positivity and plasma cells infiltration.

  2006cited by this paper
• Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.

  2006cited by this paper
• Patients with juvenile psoriatic arthritis comprise two distinct populations.

  2006cited by this paper
• Successful treatment of refractory adult onset Still’s disease with rituximab

  2006cited by this paper
• Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab.

  2006cited by this paper
• Leflunomide or methotrexate for juvenile rheumatoid arthritis.

  2005cited by this paper
• Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

  2005cited by this paper
• Radiologic investigation of rheumatic diseases.

  2005cited by this paper
• Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease.

  2005cited by this paper
• Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis?

  2005influential reference
• Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury?

  2004cited by this paper
• International League of Associations for Rheumatology: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001

  2004cited by this paper
• A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.

  2004cited by this paper

• Juvenile idiopathic arthritis and its associated uveitis

  2023cites this paper
• Emerging therapies for juvenile arthritis: agents in early clinical trials

  2022cites this paper
• Juvenile idiopathic arthritis

  2022cites this paper
• Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis

  2021cites this paper
• Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti–Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease

  2018cites this paper
• Update on the pathogenesis and treatment of juvenile idiopathic arthritis

  2017cites this paper
• Nanoparticle methotrexate delivery system for the treatment of paediatric patients with inflammatory bowel disease

  2017cites this paper
• Chapter 7 – Juvenile Idiopathic Arthritis

  2017cites this paper
• Regulation of Human Macrophage M1–M2 Polarization Balance by Hypoxia and the Triggering Receptor Expressed on Myeloid Cells-1

  2017cites this paper
• Management of Patients with Juvenile Idiopathic Arthritis

  2016cites this paper
• Clinical outcome measures in juvenile idiopathic arthritis

  2016cites this paper
• Methotrexate nanoparticle delivery system for treatment of inflammatory bowel disease in pediatric patients

  2016cites this paper
• The joints in juvenile idiopathic arthritis

  2015cites this paper
• Long-Term Safety of Immunomodulators in Pediatric Inflammatory Diseases

  2014cites this paper
• Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept

  2013cites this paper
• Paediatric rheumatology: Juvenile idiopathic arthritis—are biologic agents effective for pain?

  2013cites this paper
• Section 4: Juvenile Idiopathic Arthritis

  2013cites this paper
• Towards a role of ultrasound in children with juvenile idiopathic arthritis.

  2013cites this paper
• Osteoarthritis: Osteoporotic OA: a reasonable target for bone-acting agents

  2013cites this paper
• Ultrasound-detected synovial abnormalities are frequent in clinically inactive juvenile idiopathic arthritis, but do not predict a flare of synovitis

  2012cites this paper
• Terapia biológica en la artritis idiopática juvenil

  2012cites this paper
• Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score.

  2012cites this paper
• Toward a treat-to-target approach in the management of juvenile idiopathic arthritis.

  2012cites this paper
• Painful rheumatoid arthritis.

  2011cites this paper
• Juvenile Idiopathic Arthritis

  2000cites this paper